Drug intelligence / Profile preview

99mTc-HYNIC-EPPT

Development stage: Preclinical
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

99mTc-HYNIC-EPPT is a radiolabeled peptide-based agent designed for imaging applications. It is notably used for targeting MUC1 on the surface of cancer cells, demonstrating high affinity with Kd values around 41.77 ± 7.34 nM[3]. It is synthesized using technetium-99m and involves the use of HYNIC as a chelating agent, which allows for stable binding of the radionuclide to the peptide[3].

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on 99mTc-HYNIC-EPPT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-HYNIC-EPPT.

Explore the full profile